| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c5ddced4c203e56346f054e364b141ba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70557 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02 |
| filingDate |
1994-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ae2c37a62ccae0989a0439fbe1f6a2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29e447f57cd192a4b1a3c0d1085e7dfb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17596fe390a87023acea81728471674a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97cf22aa9f455d78fca62aba26f9b565 |
| publicationDate |
1996-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0705274-A1 |
| titleOfInvention |
Method and composition for treating thrombosis |
| abstract |
The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis. |
| priorityDate |
1993-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |